Obesity and Non-Alcoholic Fatty Liver Disease: Pathophysiology and Management Focused

Obesity and Non-Alcoholic Fatty Liver Disease: Pathophysiology and Management Focused



Abstract Views
589

Downloads
309

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

##plugins.themes.bootstrap3.article.main##

The continuing rise of obesity epidemic in the global population has been markedly associated with the escalating occurrence and severity of non-alcoholic fatty liver disease (NAFLD). This condition represents a complex metabolic imbalance, primarily characterized by excessive intrahepatic accumulation of triglycerides, known as hepatic steatosis. This pathophysiological process is initiated by the disproportionation between the uptake of dietary fatty acids in plasma, as well as the increase of de novo fatty acid synthesis, which is not equally accompanied by the exportation and oxidation of fatty acid in the form of triglycerides. As mentioned earlier, the underlying metabolic process becomes a significant risk factor for developing cardiometabolic complications, involving type 2 diabetes mellitus, insulin resistance, and dyslipidemia. This review presents a comprehensive understanding of the pathogenesis and pathophysiology of obesity and NAFLD to determine innovative management approaches for the prevention and treatment of the disease.

Keywords: Non-alcoholic fatty liver disease, obesity, lipid, metabolic disorder
  1. Chalasani, N., Younossi, Z., Lavine, J.E., et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” Hepatology, vol. 55, no. 6, pp. 2005-2023, 2012.
    DOI
     Google Scholar 
  2. Leite, N.C., Araujo, A.L., Villela-Nogueira, C.A., et al., “Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus,” Liver International: Official Journal of the International Association for the Study of the Liver, vol. 29, no. 1, pp. 113-119, 2009.
    DOI
     Google Scholar 
  3. Ogden, C.L., Carroll, M.D., Kit, B.K., et al., “Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010,” JAMA, vol. 307, no. 5, pp. 483-490, 2012.
    DOI
     Google Scholar 
  4. Tsigos, C., Hainer, V., Basdevant, A., et al., “Management of obesity in adults: European clinical practice guidelines,” Obesity Facts, vol. 1, no. 2, pp. 106-116, 2008.
    DOI
     Google Scholar 
  5. Ogden C.L., Carroll M.D., “Prevalence of overweight, obesity, and extreme obesity among adults: United States, trends 1960–1962 through 2007–2008,” National Center for Health Statistics, 2010.
    DOI
     Google Scholar 
  6. Kim, C.H., Younossi, Z.M., “Non-alcoholic fatty liver disease: a manifestation of the metabolic syndrome,” Cleveland Clinic Journal of Medicine, vol. 75, no. 10, pp. 721-728, 2008.
    DOI
     Google Scholar 
  7. Younossi, Z.M., “Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis,” Aliment Pharmacol Ther., vol. 28, pp. 2-12, 2008.
    DOI
     Google Scholar 
  8. Ahmed, A., Wong, R.J., Harrison, S.A., “Non-alcoholic fatty liver disease review: Diagnosis, treatment and outcomes,” Clin Gastroenterol Hepatol., vol. 13, pp. 2062-2070, 2015.
    DOI
     Google Scholar 
  9. Trovato, F.M., Castrogiovanni, P., Szychlinska, M.A., et al., “Early effects of high-fat diet, extra-virgin olive oil and vitamin D in a sedentary rat model of non-alcoholic fatty liver disease,” Histol Histopathol., vol. 33, pp. 1201-1213, 2018.
     Google Scholar 
  10. Cholankeril, G., Patel, R., Khurana, S., et al., “Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management,” World J Hepatol., vol. 9, pp. 533-543, 2017.
    DOI
     Google Scholar 
  11. Satapathy, S.K., Sanyal, A.J., “Epidemiology and natural history of non-alcoholic fatty liver disease,” Seminars in Liver Disease, vol. 35, no. 3, pp. 1-15, 2015.
    DOI
     Google Scholar 
  12. Vajro, P., Lenta, S., Socha, P., et al., “Diagnosis of non-alcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee,” JPGN, vol. 54, no. 5, pp. 700-713, 2012.
    DOI
     Google Scholar 
  13. Divella, R., Mazzocca, A., Daniele, A., et al., “Obesity, non-alcoholic fatty liver disease and adipocytokines network in promotion of cancer,” Int J Biol Sci., vol. 15, no. 3, pp. 610-616, 2019.
    DOI
     Google Scholar 
  14. Choi, S., Diehl, A., “Hepatic triglyceride synthesis and non-alcoholic fatty liver disease,” Curr Opin Lipidol., vol. 19, pp. 295-300, 2008.
    DOI
     Google Scholar 
  15. Rector, R.S., Thyfault, J.P., Wei, Y., et al., “Non-alcoholic fatty liver disease and the metabolic syndrome: an update,” World J Gastroenterol, vol. 14, pp. 185-192, 2008.
    DOI
     Google Scholar 
  16. Combs, T., Berg, A., Obici, S., et al., “Endogenous glucose production is inhibited by the adipose-derived protein Acrp30,” J Clin Invest., vol. 108, pp. 1875-1188, 2001.
    DOI
     Google Scholar 
  17. Rajala, M., Scherer, P., “Minireview: the adipocyte at the crossroads of energy homeostasis, inflammation, and atherosclerosis,” Endocrinology, vol. 144, pp. 3765-3773, 2003.
    DOI
     Google Scholar 
  18. Li, Z., Yang, S., Lin, H, et al., “Probiotics and antibodies to TNF inhibit inflammatory activity and improve non-alcoholic fatty liver disease,” Hepatology, vol. 37, pp. 343-359, 2003.
    DOI
     Google Scholar 
  19. Unger, R., “Lipotoxic diseases,” Annu Rev Med., vol. 53, pp. 319-336, 2002.
    DOI
     Google Scholar 
  20. Leclercq, I.A., Farrell, G.C., Schriemer, R., et al., “Leptin is essential for the hepatic fibrogenic response to chronic liver injury,” J Hepatol., vol. 27, pp. 206-213, 2002.
    DOI
     Google Scholar 
  21. Bugianesi, E., McCullough, A., Marchesini, G., “Insulin resistance: A metabolic pathway to chronic liver disease,” Hepatology, vol. 42, pp. 987-1000, 2005.
    DOI
     Google Scholar 
  22. Jiang, J., Torok, N., “Non-alcoholic steatohepatitis and the metabolic syndrome,” Metab Syndr Relat Disord., vol. 6, pp. 1-8, 2005.
     Google Scholar 
  23. Angulo P., “Non-alcoholic fatty liver disease,” N Engl J Med., vol. 346, pp. 1221-1231, 2002.
    DOI
     Google Scholar 
  24. Polyzos, S.A., Kountouras, J., Mantzoros, C.S., “Adipose tissue, obesity and non-alcoholic fatty liver disease,” Minerva Endocrinol., vol. 42, pp. 92-108, 2017.
    DOI
     Google Scholar 
  25. Mota, M., Banini, B.A., Cazanave, S.C., et al., “Molecular mechanisms of lipotoxicity and glucotoxicity in non-alcoholic fatty liver disease,” Metabolism, vol. 65, pp. 1049-1061, 2016.
    DOI
     Google Scholar 
  26. Tordjman, J., Guerre-Millo, M., Clement, K., “Adipose tissue inflammation and liver pathology in human obesity,” Diabetes Metab., vol. 34, pp. 658-663, 2008.
    DOI
     Google Scholar 
  27. Nati, M., Haddad, D., Birkenfeld, A.L., et al., “The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH),” Rev Endocr Metab Disord., vol. 17, pp. 29-39, 2016.
    DOI
     Google Scholar 
  28. National Institute for Health and Care Excellence (UK), “Non-alcoholic fatty liver disease: assessment and management,” Available from http://www.niceorg.ukguidanceng49.
     Google Scholar 
  29. Paul, J., Venugopal, R.V., Peter, L., et al., “Effects of lifestyle modification on liver enzyme and Fibroscan in Indian patients with non-alcoholic fatty liver disease,” Gastroenterol Rep., vol. 6, pp. 49-53, 2018.
    DOI
     Google Scholar 
  30. Saab, S., Mallam, D., Cox, G.A., et al., “Impact of coffee on liver diseases: a systematic review,” Liver Int, vol. 34, pp. 495-504, 2014.
    DOI
     Google Scholar 
  31. Setiawan, V.W., Porcel, J., Wei, P., et al., “Coffee drinking and alcoholic and non-alcoholic fatty liver diseases and viral hepatitis in the multiethnic cohort,” Clin Gastroenterol Hepatol., vol. 15, no. 8, pp. 1305-1307, 2017.
    DOI
     Google Scholar 
  32. Wenxia, L., Sainan, L., Jingjing, L., et al., “Effects of omega-3 fatty acid in non-alcoholic fatty liver disease: a meta-analysis,” Gastroenterol Res Pract., vol. 2016, no. 1459790, 2016.
     Google Scholar 
  33. Salomone, F., Galvano, F., Li, V.G., “Molecular bases underlying the hepatoprotective effects of coffee,” Nutrients, vol. 9, no. 1, pp. 85, 2017.
    DOI
     Google Scholar 
  34. Marchesini, G., Day, C.P., Dufour, J.F., et al., “EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease,” J Hepatol., vol. 64, pp. 1388-1402, 2016.
    DOI
     Google Scholar 
  35. US Department of Agriculture. Available at: www.choosemyplate.gov; and American Heart Association. Available at: www.heart.org.
     Google Scholar 
  36. Kargulewicz, A., Stankowiak-Kulpa, H., Grzymislawski, M., “Dietary recommendations for patients with non-alcoholic fatty liver disease,” Prz Gastroenterol., vol. 9, no. 1, pp. 18-23, 2014.
    DOI
     Google Scholar 
  37. Zelber-Sagi, S., Kessler, A., Brazowsky, E., et al., “A double-blind randomized placebo-controlled trial of orlistat for the treatment of non-alcoholic fatty liver disease,” Clin Gastroenterol Hepatol., vol. 4, pp. 639-644, 2006.
    DOI
     Google Scholar 
  38. Harrison, S.A., Brunt, E.M., Fecht, W.J., et al., “Orlistat for overweight subjects with non-alcoholic steatohepatitis (NASH): a randomized prospective trial,” Hepatology, vol. 49, pp. 80-86, 2009.
    DOI
     Google Scholar 
  39. Uygun, A., Kadayifci, A., Isik, A.T., et al., “Metformin in the treatment of patients with non-alcoholic steatohepatitis,” Aliment Pharmacol Ther., vol. 19, pp. 537-544, 2004.
    DOI
     Google Scholar 
  40. Belfort, R., Harrison, S.A., Brown, K., et al., “A placebo-controlled trial of pioglitazone in subjects with non-alcoholic steatohepatitis,” N Engl J Med., vol. 355, pp. 2297-2307, 2006.
    DOI
     Google Scholar 
  41. Sanyal, A.J., Chalasani, N., Kowdley, K.V., et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” N Engl J Med., vol. 362, pp. 1675-1685, 2010.
    DOI
     Google Scholar 
  42. Lincoff, A., Wolski, K., Nicholls, S., et al., “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,” JAMA, vol. 298, pp. 1180- 1188, 2007.
    DOI
     Google Scholar 
  43. Harrison, S.A., Torgerson, S., Hayashi, P., et al., “Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis,” Am J Gastroenterol, vol. 98, pp. 2485-2490, 2003.
    DOI
     Google Scholar 
  44. Sanyal, A.J., Mofrad, P.S., Contos, M.J., et al., “A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of non-alcoholic steatohepatitis,” Clin Gastroenterol Hepatol., vol. 2, pp. 1107-1115, 2004.
    DOI
     Google Scholar 
  45. Klein, E.A., Thompson, I.M., Tangen, C.M., et al., “Vitamin E and the risk of prostate cancer. The selenium and vitamin E cancer prevention trial (SELECT),” JAMA, vol. 306, pp. 1549-1556, 2011.
    DOI
     Google Scholar 
  46. Leushner, U., Lindenthal, B., Herrman, G., et al., “High-dose ursodeoxycholic acid therapy for non-alcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial,” Hepatology, vol. 52, pp. 472-479, 2010.
    DOI
     Google Scholar 
  47. Ratziu, V., de Ledinghen, V., Oberti, F., et al., “A randomized controlled trial of high-dose ursodeoxycholic acid for non-alcoholic steatohepatitis,” J Hepatol., vol. 54, pp. 1011-1019, 2011.
    DOI
     Google Scholar 
  48. Spadaro, L., Magliocco, O., Spampinato, D., et al., “Effects of n-3 polyunsaturated fatty acids in subjects with non-alcoholic fatty liver disease,” Dig Liver Dis., vol. 40, pp. 194-199, 2008.
    DOI
     Google Scholar 
  49. Lewis, J.H., Mortensen, M.E., Zweig, S., et al. in Chronic Liver Disease Study Investigators, “Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial,” Hepatology, vol. 46, no. 5, pp. 1453-1463, 2007.
    DOI
     Google Scholar 
  50. Nelson, A, Torres, D.M., Morgan, A.E., et al., “A pilot study using simvastatin in the treatment of non-alcoholic steatohepatitis: a randomized placebo-controlled trial,” J Clin Gastroenterol., vol. 43, pp. 990-994, 2009.
    DOI
     Google Scholar 
  51. Zolfaghari, H., Askari, G., Siassi, F., et al., “Intake of nutrients, fiber, and sugar in patients with non-alcoholic fatty liver disease in comparison to healthy individuals,” Int J Prev Med., vol. 7, no. 98, 2016.
    DOI
     Google Scholar 
  52. Beilfuss, A., Sowa, J.P., Sydor, S., et al., “Vitamin D counteracts fibrogenic TGF-beta signalling in human hepatic stellate cells both receptor-dependently and independently,” Gut, vol. 64, pp. 791-799, 2015.
    DOI
     Google Scholar 
  53. Amiri, H.L., Agah, S., Mousavi, S.N., et al., “Regression of non-alcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial,” Arch Iran Med, vol. 19, no. 9, pp. 631-638, 2016.
     Google Scholar 

Downloads

Download data is not yet available.
Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Febyan, ., & Weky, N. D. (2021). Obesity and Non-Alcoholic Fatty Liver Disease: Pathophysiology and Management Focused. European Journal of Medical and Health Sciences, 3(1), 6–12. https://doi.org/10.24018/ejmed.2021.3.1.645

Search Panel

 . Febyan
 Google Scholar
 PUBMED
 EJMED Journal
 Norman Delvano Weky
 Google Scholar
 PUBMED
 EJMED Journal